2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2534

the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study
Abstract Number: 2535

Patient Outcomes from a Tertiary Center Combined Rheumatology-Dermatology Clinic
Abstract Number: 2536

Comparison of Quality-of-Life, Function and Psoriasis Measures in Minimal Disease Activity and DAS28 States in Routine Care of Patients with Psoriatic Arthritis
Abstract Number: 2537

Changes in Severity, Functional Status, and Wellbeing over Time Among Individuals with Ankylosing Spondylitis (AS) in Canada: Results from the RHUMADATA® Multicentre Registry
Abstract Number: 2538

Change in Self-Reported Health Status and Fatigue before and after the Diagnosis of Psoriatic Arthritis- the Nord-Trondelag Health Study (HUNT)
Abstract Number: 2539

The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Abstract Number: 2540

Impact of Sleep on Measures of Disease Activity in Psoriatic Arthritis
Abstract Number: 2541

The Relationship between the Patient Acceptable Symptom State (PASS) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
Abstract Number: 2542

Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis
Abstract Number: 2543

Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity
Abstract Number: 2544

Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact
Abstract Number: 2545

Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis
Abstract Number: 2546

Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Abstract Number: 2547

the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Abstract Number: 2548

Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].